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Abstract
In addition to sporadic primary neoplasms of the central nervous system, several genetic 
syndromes associated with CNS tumors have been identified. Tuberous sclerosis, neu-
rofibromatosis-1 and -2, and von Hippel–Lindau syndrome belong to a collection of 
disorders called phakomatoses, which include both CNS tumors and cutaneous manifes-
tations. The underlying genetics of these disorders are being elucidated and offer novel 
therapies for intervention.
Keywords: genetic, phakomatosis, tuberous sclerosis, neurofibromatosis, von 
Hippel–Lindau
1. Introduction
Phakomatoses are disorders which, in addition to skin manifestations, can lead to the devel-
opment of tumors within the central and peripheral nervous systems. Due to extensive organ 
involvement and the complex genetics pathways involved, treatment options are limited. 
Some of these genetic disorders involve abnormal neural crest migration or terminal differen-
tiation, and tumor suppressor gene dysfunction. These may exhibit autosomal dominant or 
X-linked recessive inheritance.
Central nervous system manifestations include seizure, stroke, hearing loss secondary to 
tumor growth, visual loss secondary to optic gliomas, hydrocephalus, and cognitive deficits, 
while peripheral manifestations include sensory loss or motor weakness from neurofibromas. 
The cutaneous manifestations of these disorders are usually ectodermal in origin and can 
and range from small lesions to involvement of entire dermatomes. The common disorders 
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leading to tumor development are tuberous sclerosis, neurofibromatosis-1 and -2, and von 
Hippel–Lindau syndrome. Ataxia-telangiectasia and Sturge–Weber syndrome are phakoma-
toses that do not typically lead to tumor development and will not be discussed here.
2. Tuberous sclerosis
2.1. Introduction
Tuberous sclerosis complex (TSC) is a disorder affecting 1:5000–1:10,000 live births [1] char-
acterized by the formation of hamartomas throughout the brain and skin with the formation 
of renal, pulmonary, and cardiac tumors [2]. It is thought to be caused by mutations in two 
genes: TSC1on chromosome 9q34 encoding hamartin [3] and TSC2 on chromosome 16p13 
encoding tuberin [4]. These mutations result in varying degrees of upregulation of the mTOR 
pathway. About 10–15% of TSC patients do not have mutations in TSC1 or TSC2, however. 
While often inherited in an autosomal dominant fashion, two-thirds of patients have de novo 
mutations [5].
Patients most often present in the first year of life with seizures, typically focal seizures or 
infantile spasms. The latter are closely associated with cognitive impairments but they typi-
cally respond to vigabatrin [6]. A spectrum of cognitive, behavioral, neuropsychiatric, and 
intellectual disabilities has been described known as TSC-associated neuropsychiatric dis-
orders (TAND), for which there is currently inadequate screening and no approved treat-
ment [7]. Within the brain are found tubers within the cortex and subependymal nodules 
(SEN) along the walls of the lateral and third ventricles. SEN may transform into subepen-
dymal giant cell astrocytomas (SEGA). Retinal astrocytic hamartomas occur in 30–50% of 
TSC patients and most remain stable over time. They are typically asymptomatic unless they 
involve the macula or optic nerve [8].
Approximately, 55–80% of patients with TSC have renal involvement including renal cysts, 
polycystic kidney disease (PKD), and angiomyolipomas (AML) [9]. The Polycystin-1 gene 
(PKD-1), mutations in which lead to polycystic kidney disease, is downstream of TSC2 and a 
TSC2/PKD1 contiguous gene syndrome has been described in which deletions affecting both 
genes lead to TSC with early-onset renal polycystic disease [10]. AML are benign tumors with 
components of abnormal blood vessels, immature smooth muscle, and mature adipose tissue. 
They are often multiple, bilateral, and grow mainly during childhood, remaining relatively 
stable in adulthood [11]. They are associated with an increased risk of micro- and macro-
aneurysms [12]. Sequelae of the renal manifestations of TSC include an increased risk of hem-
orrhage from abnormal vasculature, chronic kidney disease, and hypertension.
In TSC, cardiac rhabdomyomas occur, which are more common in neonates and may spon-
taneously regress throughout childhood. They occur in 20% of adults with TSC. Most are 
asymptomatic, though arrhythmias including Wolff-Parkinson-White syndrome or outflow 
obstruction may occur, warranting treatment [13].
Lymphangioleiomyomatosis is an uncommon progressive cystic lung disease affecting 
30% of women and a milder form in 10% of men with TSC, associated with mutations in 
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the TSC2 gene. Abnormal smooth muscle cells proliferate and infiltrate into alveoli, blood 
vessels, and lymphatics causing obstructive airway disease and blood vessel and lymphatic 
obstruction leading to dyspnea, pneumothorax, and chylous pleural effusion [14].
The neurocutaneous manifestations of TSC are present in over 90% of patients and include 
hypomelanotic macules (87–100%), shagreen patches (20–80%), ungual fibromas (17–87%), 
and angiofibromas (47–90%) [15].
2.2. Diagnosis
The pathogenesis of TSC is thought to be due in part to changes in neural crest function. 
Neural crest cells arise from embryonic ectoderm and give rise to a number of diverse cell 
lineages including melanocytes. Cutaneous lesions, particularly hypomelanotic macules 
and shagreen patches, are due in part to abnormal segmental melanocytic distribution and 
the characteristic dermal facial angiofibromas are derived from mesencephalic neural crest. 
Cortical tubers and hamartomas in the periventricular region and are not neural crest deriva-
tives, however [16].
Cortical tubers are developmental in origin and histologically show effacement of the laminar 
architecture with gliosis, micro-calcifications, large multinucleated cells with glassy, bright 
eosinophilic cytoplasm, and dysmorphic neurons. These neurons appear “immature” with 
poorly differentiated cell processes, abundant eosinophilic cytoplasm, and disrupted orienta-
tion within the cortical lamina. These structures are believed to be responsible for seizures in 
TSC patients [17]. Subependymal nodules (SEN) are neoplasms that develop along the walls 
of the lateral ventricles and can calcify within the first few years of life. These may subse-
quently develop into subependymal giant cell astrocytoma [18].
SEGA typically develop from SEN in the first two decades of life and present clinically with 
worsening epilepsy or increased intracranial pressure from obstructive hydrocephalus. These 
mixed glioneural tumors tend to be well-circumscribed with a variety of tumor cell mor-
phologies including large pleomorphic, multinucleated gemistocytic astrocytes, and small, 
spindle-shaped astrocytes as well as giant ganglionic pyramidal cells (Figure 1). Perivascular 
pseudorosettes and calcifications are commonly seen. These benign tumors have a low (1–7%) 
mitotic index and correspond to WHO grade I. Immunohistochemistry demonstrates immu-
noreactivity for both glial (S-100 and GFAP) and neural (neurofilament, class III β-tubulin, 
and synaptophysin) markers, again emphasizing the divergent glioneuronal origin of these 
tumors [19]. Because the ependyma remains intact over SEGA, dissemination of tumor cells 
into the CSF is rare.
Radiographically, cortical tubers appear as areas of increased cortical and subcortical inten-
sity on T2-weighted magnetic resonance imaging (MRI) and rarely enhance with gadolinium 
[20]. In contrast, cerebellar tubers are usually wedge-shaped and distort the architecture of 
the folia. Up to half are calcified and may enhance with gadolinium. They are not epilep-
togenic and can change in size or enhancement over the first decade of life. Subependymal 
 nodules are T1 hyper-intense and T2 hypo-intense lesions along the lateral ventricles that 
often enhance with gadolinium and are described as having the appearance of “candle drip-
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pings” [21]. SEGA appear as round to ovoid lesions that are iso- to hypo-intense on T1 MRI 
and hyper-intense on T2 MRI. They often avidly enhance with gadolinium and calcification 
and hemorrhage may be seen (Figure 2). In addition, radial migration lines may be seen on 
FLAIR images that represent gliosis resulting from aberrant glial neuronal migration [22].
2.3. Genetics
Mutations in two genes have been identified that lead to TSC. TSC1 on chromosome 9q34 
encodes a 130 kDa protein called hamartin and TSC2 on chromosome 16p13 encodes the 200 
kDa protein tuberin. TSC2 mutations are more common and are associated with a more severe 
phenotype [2]. These two proteins form a heterodimeric complex that integrates signals from 
various pathways involved in regulating cellular responses to environmental stress and 
energy status (Figure 3). TSC2 contains a GTP-activating domain (GAP) that has been shown 
to activate the small GTPase Rheb [23], which in turn activates mechanistic target of rapamy-
cin complex-1 (mTORC1). mTORC1 is a serine-threonine protein kinase complex whose 
activation leads to cell growth and differentiation by inhibiting autophagy and  promoting 
protein and lipid synthesis through the phosphatidylinositol 3-kinase-related kinase signal-
ing pathway [24]. TSC1 has no catalytic function and serves to stabilize TSC2 [25].
Figure 1. SEGA histology: large cells with abundant cytoplasm and prominent nucleoli, and a perivascular fibrillary area.
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TSC1/2 is regulated by a number of factors. Many growth factors and cytokines act through 
AKT (protein kinase B), which inhibits TSC1/2 by phosphorylating TSC2 ([26]. Ribosomal S6 
kinase (RSK) activates extracellular signal-regulated kinase (ERK), which then phosphorylates 
and inactivates TSC2. RSK also directly phosphorylates TSC2 [27]. A number of environmen-
tal cues lead to TSC1/TSC2 activation. Environmental stress leading to low ATP/AMP ratio 
leads to activation of AMP-dependent protein kinase (AMPK) that phosphorylates and acti-
vates TSC2. Hypoxia induces expression of hypoxia-inducible factor-α (HIF1α) that induces 
REDD1, which indirectly activates TSC1-TSC2 by removing AKT dependent inhibition [28].
The mTOR1 complex (mTORC1) is a multimeric complex consisting of deptor, PRAS40, rap-
tor, mLST8, mTOR, and TTI1–TEL and effects changes in several important cellular processes 
[24]. mTORC1 promotes protein synthesis through activation of the translation initiation pro-
moter S6K and through inhibition of the inhibitory mRNA cap binding 4E-BP1. This pathway 
is thought to play a role in formation of hamartomas. mTORC1 inhibits autophagy through 
inhibitory phosphorylation of ULK1, preventing formation of the ULK1–ATG13–FIP200 com-
plex required for initiation of autophagy [29]. Increased mTORC1 signaling may cause hypo-
pigmented macules by affecting autophagy during melanogenesis.
Recently, TBC1D7 has been identified as a third subunit in the TSC1/TSC2 complex. This pro-
tein does not seem to reflect changes in cellular growth conditions, but loss of TBC1D7 leads 
to destabilization of TSC1/TSC2 and decreased Rheb-GAP activity [30].
2.4. Treatment
TSC offers a lifetime of treatment challenges for the various manifestations the disease 
including seizure control, management of cognitive and behavioral effects, and treatment 
for and monitoring of SEGA. For asymptomatic tumors, surveillance with gadolinium-
enhanced MRI every 1–3 year in children and yearly in adults is recommended [31]. Surgery 
is recommended for symptomatic tumors or asymptomatic tumors in which growth or 
Figure 2. Subependymal Giant Cell Asrocytoma: (a) MRI axial T1 with gadolinium (b) MRI axial T2 FLAIR (c) Head CT 
showing prominent calcification.
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increase in ventricle size has occurred. Complete resection is curative, but incomplete 
resection may lead to tumor regrowth [32, 33], and ventriculoperitoneal shunting is often 
employed in addition to or in place of tumor resection in order to address the obstructive 
hydrocephalus resulting from SEGA growth at the foramen of Monro. Though radiation 
therapy has also been used to treat SEGA, it is not the standard of care and radiation-
induced neoplasms have been reported [34].
Because TSC is caused by mutations in tumor suppressor genes leading to upregulation 
of the mTOR pathway, various mTOR inhibitors have been investigated as possible candi-
Figure 3. TSC 1 stabilizes TSC2 which is activated by AMPK and inhibited by AKT. The GAP domain of TSC2 inactivates 
mTORC1 by dephosphorylating GTP associated with Rheb (adapted with permission from Ref. [30]).
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dates to treat TSC. Inhibition of mTOR by rapamycin was shown to reduce the size of SEGA 
[35, 36], renal angiolipomas [37] lymphangioleiomyomatosis [38], and facial angiofibromas 
[39]. Everolimus [40], a derivative of rapamycin and an inhibitor of mTORC-1, was sub-
sequently chosen as a possible therapy for patients with TSC. In a prospective, open-label 
Phase 2 study of 28 patients with SEGA, treatment with everolimus for 6 months resulted 
in reduction in tumor volume and seizure frequency was largely stable to improved [41]. 
This lead to a larger Phase 3 trial in which 117 adults with SEGA were randomized to 
receive either everolimus or placebo. Patients in the treatment group were found to have 
at least a 50% reduction in tumor volume versus the placebo group. Adverse effects were 
mostly mild and included seizures and stomatitis [35]. Consequently, in 2010, everolimus 
was FDA-approved for treatment of patients with SEGA that require therapeutic interven-
tion but cannot be curatively resected.
2.5. Future directions
Treatment of TSC involves management of symptomatic SEGA, and recently, everolimus and 
rapamycin have offered a medical therapy to supplement surgery in treating these slow-grow-
ing but clinically important tumors. Currently, these agents are being investigated to manage 
other manifestations of TSC. Topical rapamycin is being studied to treat facial angiofibromas, 
and both rapamycin and everolimus are being investigated as treatment for renal angiomyo-
lipoma. As the genetics of TSC are better understood, new molecular targets are likely to be 
discovered allowing novel pharmacologic agents the ability to improve the quality of life for 
patients afflicted with TSC.
3. Neurofibromatosis 1
3.1. Introduction
Neurofibromatosis Type 1 (NF1), also known as von Recklinghausen disease, is one of 
the most common autosomal dominant neurogenic disorders. NF1 affects about 1 in 3000 
live births [42] and is sometimes referred as peripheral neurofibromatosis. Although the 
penetrance is autosomal dominant, there are about 50% sporadic mutations as well. The 
NF-1 gene is a tumor suppressor gene located on chromosome 17 (17q11.2) [43] and 
encodes the 250 kDa protein neurofibromas, which is involved in the regulation of the 
RAS family proto-oncogenes and in the mTOR pathway. The RAS pathway involves a 
complex downward complex pathway involved in cell differentiation and cell growth 
through GTP signaling. Mutations in the RAS gene can cause permanent cellular trans-
duction consequently causing increased cellular proliferation causing tumor growth 
[44].
3.2. Diagnosis
The diagnostic criteria of neurofibromatosis include the presence of two or more of the 
following:
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1. First degree relative with NF1.
2. Axillary of inguinal freckling.
3. Two or more neurofibromas or 1 plexiform neurofibroma.
4. Optic glioma.
5. Osseous lesions.
6. Two or more Lisch nodules.
7. Six or more café au lait spots measuring more than 5 mm in prepubertal individuals or 
more than 15 mm in postpubertal individuals number [45].
Genetic testing is of diagnostic importance but would not be able to predict the disease severity 
and outcome. Clinical manifestations of the disease include cutaneous manifestations such as 
cafe au lait spots, facial, and axillary freckling (Crowe’s sign), generalized hyperpigmentation, 
juvenile xanthogranuloma, Lisch nodules (pigmented hamartomas of the iris), pseudoatrophic 
macules, and nevus anemicus (a congenital vascular anomaly that presents as a hypopigmented 
macule or patch). Glomus tumors, benign neoplasms arising from the glomus body of the der-
mis often occur under the nail or on the fingertips of patients with NF1, as does an increased 
incidence of melanoma. In addition, NF1 is associated with scoliosis, dysplasia of long bone 
(sphenoid wing dysplasia), macrocephaly, short stature, learning disabilities, and ADHD. Of 
course, the hallmark of NF1 is the presence of cutaneous and plexiform neurofibromas, benign 
(WHO Grade I) nerve sheath tumors arising from nonmyelinating Schwann cells which typi-
cally surround small diameter peripheral axons. In contrast, myelinating Schwann cells cover 
larger diameter peripheral axons and are not tumorigenic. Histologically, neurofibromas 
consist of elongated wavy cells with small dark oblong nuclei. The tumor is characterized by 
tortuous proliferation of all components of peripheral nerves including axons, Schwann cells, 
fibroblasts, and perineural cells. Plexiform neurofibromas are typically larger tumors with more 
extensive involvement and have the potential to transform into malignant peripheral nerve 
sheath tumors (MPNST), sarcomas that typically appear in adulthood. About half of MPSNT 
occur in patients with NF1 [46]. Optic Gliomas are benign tumors of the optic nerve, chiasm, or 
tract that affect 15–40% of children with NF1 [47]. They typically present with painless vision 
loss or proptosis and may demonstrate an afferent pupillary defect and optic nerve pallor.
3.3. Genetics
The NF1 gene encodes a large cytosolic protein called neurofibromin and has one of the 
highest rates of mutations in the human genome. It is about 60 exon and 300 KB of genomic 
DNA [48]. NF1 is an autosomal dominant disorder, but sporadic mutation occurs in about 
50% of patients. The symptoms usually start around age 10 and the penetrance reaches 
100% by age 20. NF1 is associated with many other cancers systemically including gliomas, 
pheochromocytoma, juvenile myelomonocytic leukemia as well as meningioma [49]. NF1 is 
expressed in neurons, oligodendrocytes, and Schwann cells, and acts as a tumor suppres-
sor by negatively regulating signaling through the Ras pathway by virtue of its GTPase-
activating protein (GAP) domain [50]. Over one thousand mutations have been identified in 
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NF1which lead to upregulation of the Ras signaling pathway leading to cell proliferation, 
migration, and differentiation.
3.4. Treatment
As per the guidelines from American Academy of Pediatrics children with NF1, routine 
MRI, EEG, and other imaging of the peripheral nervous system are no longer recommended. 
Instead they recommend getting routine neurological and ophthalmological examination 
unless specific other needs arises to image CNS and PNS. With the multitude of symptoms 
of neurofibromatosis 1, the treatment options available are limited. Surgery may be used to 
remove painful peripheral neurofibromas but is typically withheld for asymptomatic lesions. 
Resection is not possible for optic gliomas, though optic sheath fenestration is possible as is 
debulking of plexiform neurofibromas that involve the orbit.
Although radiation is used to control the local spread of these tumors in the CNS, they are 
side effects including emergence of other malignancies in the CNS, which limit their use [51]. 
Neurofibromas are generally considered to be chemoresistant but various chemotherapeutic 
agents have been investigated to treat MPNST including doxirubicin and ifosfamide but none 
have shown improvement in recurrence or survival.
3.5. Future directions
Although most of the management of NF1 is symptomatic, clinical trials are being performed 
to evaluate lovastatin [52] and lamotrigine [53], see whether these agents help with neurocog-
nitive dysfunction. Rapamycin, an MTOR inhibitor, is being investigated as treatment for the 
plexiform neurofibromas but has not shown an effect on tumor size, though pain is improved 
with treatment [54, 55].
Imatinib, a tyrosine kinase inhibitor, shows promise in reducing the size of peripheral neuro-
fibromas [56, 57]. Carboplatin and vincristine have also showed promise in treating low-grade 
gliomas in children with NF1 [58]. Topical vitamin D3 analogues had measurable clinical and 
histological effects for cutaneous lesions with notable lightening of the lesions and an increase 
in melanin incontinence.
4. Neurofibromatosis 2
4.1. Introduction
NF2 is also sometimes called central neurofibromatosis due to its predilection towards cranial 
nerve 8 and meningioma. It accounts for only 5–10% cases of all neurofibromas [59, 60], and 
there are few if any cutaneous findings. NF2 is an autosomal dominant disorder caused by 
the mutation in the merlin or schwannomin gene on chromosome 22 (q11–13.1). The pre-
cise mechanism as how this tumor suppressor gene manifests the disease is still not clear, 
but some of the studies have suggested gene activation signaling pathway in glioma tumor 
suppression [61]. The incidence of this disease is 1:25,000 [62], and it usually presents dur-
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ing adolescence with hearing loss and imbalance secondary to vestibular schwannoma. This 
disease is associated with the development of schwannoma, meningiomas, and other neural 
tumors. The disease course of the NF2 varies from individuals with mean age of onset of 
22 years of age, and mean survival from diagnosis was 15 years and mean age of death at 
approximately 42 years of age [63]. The most common cause of mortality in NF2 is from 
rapid tumor growth causing increased intracranial pressure and compression of the brain 
stem. Morbidity is greatly increased with bilateral deafness and vestibular dysfunction. 
Usually, the earlier age of onset is associated with rapid growth in the tumor than a later 
age onset [64].
4.2. Diagnosis
The diagnostic criteria for NF2 (the Manchester criteria) requires one of the following:
1. bilateral Vestibular Schwannoma (VS)
2. one or more 1st degree relative with NF2 + unilateral vestibular schwannoma at <30 years
3. two of the following: multiple meningioma, glioma, schwannoma, juvenile posterior len-
ticular opacities
NF2 may present clinically with hearing loss or tinnitus or the sequelae of intracranial glioma 
or meningioma and schwannoma. Ophthalmological manifestations including juvenile poste-
rior subcapsular cataracts, cortical wedge cataracts, retinal hamartomas, and epiretinal mem-
branes. Cutaneous features are similar but less prominent than those in NF1.
Vestibular schwannoma are Grade I tumors, which histologically demonstrate uniformly spin-
dled Schwann cells with Antonin A (cellular fascicular) and Antoni B (myxoid; vacuolated) 
regions. Nuclear pleomorphism, xanthomatous change, and vascular hyalinization are com-
mon, and Rosenthal fibers (bundles of clumped intermediate filament proteins) may be present.
4.3. Genetics
NF2 is an autosomal dominant disorder, although about 50% of the individuals were also 
found to have spontaneous mutations with no prior family history of NF2. Although the 
transmission risk is 50% in subsequent generations in parents who have NF2 and is <50% in 
isolated patients due to mosaics [65]. Tumor linkage analysis genetic testing is a great tool in 
patients who have sporadic mutation [66].
The NF2 gene product, merlin, is a scaffolding protein linking actin filaments to membrane 
glycoproteins, and its tumor suppression properties may be due to effects on contact-medi-
ated growth inhibition, though the mechanism is currently poorly understood.
4.4. Treatment
The goal of management of patient with NF2 is to preserve quality of life. Genetic counseling 
is available to first-degree relatives of affected individuals. Regular MRI screening every 2 
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years for those high-risk individuals <20-year old and every 3–5 years for those age >20 years 
should be sufficient. In high-risk patient with positive family history, initial screening can be 
even started at age 10 years and they are after annual MRI should be sufficient [67]. Regular 
neurological examination is also of prime importance in these patients. Close surveillance is 
the key after successful surgery to look for any recurrences.
Surgery for vestibular schwannomas carries the risk of hearing loss [68] and possible injury 
to the facial nerve [69]. The typical treatment for vestibular schwannoma associated with 
neurofibromatosis is stereotactic radiosurgery with gamma knife [70]. This type of surgery 
is associated with better outcome in terms of hearing preservation in about of the patients. 
This is also associated with reduced recurrence of the tumor in one the study by decreasing 
the volume of tumor by 33%. [71, 72]. Although a number of complications have also been 
reported with surgical removal of the VS including air embolism, ICH, Ischemic stroke in 
the first 3 days of surgery. In one of the study, removal of contralateral VS was associated 
with increased growth of the other VS after surgery. Due to close proximity of the facial 
nerve, there are numerous facial nerve complications that can increase the morbidity in sur-
gical patient [73]. Spinal meningiomas and schwannomas if producing neurological com-
plications would need emergent surgery but in asymptomatic patients, they can be closely 
observed [67].
4.5. Future directions
The vascular endothelial growth factor (VEGF) inhibitors, PTC 299, and bevacizumab [74] 
have been studied for treatment of vestibular schwannomas in NF2 patients with some 
improvement in tumor size and hearing function. Lapatinib, which inhibits the tyrosine 
kinase associated with epidermal growth factor receptor and HER2/neu, has shown prom-
ise in adult and pediatric NF2 patients with progressive vestibular schwannomas. Newer 
gene therapy involving oncolytic recombinant herpes simplex vector has also been shown to 
reduce volume of the tumor. Curcumin, a HSP 90 inhibitor is also another potential pathway 
target but still in early part of development [75, 76].
5. Von Hippel–Lindau syndrome
5.1. Introduction
Von Hippel–Lindau (VHL) syndrome is an autosomal dominant disorder characterized by 
visceral cysts and benign tumors in multiple organ systems that have subsequent potential for 
malignant change. The disease is named after the German ophthalmologist Eugen von Hippel 
and the Swedish Pathologist Arvid Lindau. These tumors mainly include hemangioblastomas 
of CNS and retina (60–65%), renal cysts and carcinomas (40–45%). Tumors that occur less 
frequently include endolymphatic sac tumor, adrenal pheochromocytoma, epididymal, and 
broad ligament cystadenomas. A clinical classification system divides individuals who are 
affected by VHL disease into two groups: Those predominantly without pheochromocytoma 
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are classified as VHL type 1, and those predominantly with pheochromocytoma classified as 
VHL type 2. VHL type 2 is further subdivided into type 2A (with renal cancer) and type 2B 
(without renal cancer). In type 2C, affected patients develop solely pheochromocytoma. The 
incidence of VHL disease in the United States is approximately 1 case in 36,000 live births. 
Males and females are affected equally, and it affects people of all ethnic groups. Age at diag-
nosis varies from infancy to age 60–70 years of age, with an average of 26 years [77].
5.2. Diagnosis
Von Hippel–Lindau (VHL) affects selective organs with the development of hemangioblasto-
mas. This disease should be considered when hemangioblastomas is diagnosed before third 
decade, spinal cord is involved, and there are multiple other CNS or peripheral lesions. Melon 
and Rosen established diagnostic criteria for von Hippel–Lindau disease; for diagnosis, a 
patient must have at least 1 characteristic lesion in the central nervous system, eye, or viscera 
if there is a family history of an affected first-degree relative, or they must have 2 lesions in 
the absence of a family history [78]. Diagnosis is established by contrast enhanced MRI of the 
head and spine which characteristically identifies a solid-enhancing nodule associated with a 
pseudocyst or syrinx for CNS hemangioblastomas.
Signs and symptoms of hemangioblastomas are determined by tumor site, edema associated 
with it, cyst formation and spread. Absolute size and the rate of growth does not dictate the 
symptoms for tumors in all locations and the likely time for symptoms to appear for individ-
ual lesions remains unclear because of the saltatory growth pattern exhibited by many tumors 
[79]. A number of tumor types and organ systems are affected in VHL:
1. CNS hemangioblastomas are the main component of VHL disease that may occur either 
synchronously or metachronously. Roughly, 80% develop in the brain and 20% in the spi-
nal cord. Growth patterns of these lesions can be saltatory (72%), linear (6%), or expo-
nential (22%). Increased growth of CNS HGB was associated with male sex, younger age 
group, symptomatic tumors and hemangioblastoma-associated cysts. This indicates the 
role of biological features related to developmental processes, hormonal factors, other sys-
temic factors, and/or proteasomal processing [79]. Recent studies show that pregnancy has 
no impact on CNS hemangioblastoma development or progression [80]. Within the brain, 
the majority are infratentorial, mostly in the cerebellar hemisphere. Supratentorial heman-
gioblastomas mostly develop in pituitary stalk. Headache, vomiting, and gait disturbances 
or ataxia is seen with infratentorial tumors; with tumors above the tentorium, symptoms 
depend on the location of the lesion.
2. Spinal tumors are mostly intradural, involving cervical or thoracic regions most frequently. 
Most symptom-producing spinal hemangioblastomas are associated with cysts/syringo-
myelia/syrinx [81]. They usually present with pain; cord compression may lead to sensory 
and motor loss.
3. Retinal hemangioblastomas, sometimes called retinal angiomas, are histologically iden-
tical to CNS hemangioblastomas. They may be the early manifestations of VHL syn-
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drome and can occur in childhood with mean age of detection about 25 years. They 
are mostly located in the temporal periphery of the retina 90% or may develop in the 
posterior pole (1%) and optic disc (8%) [82]. Retinal hemangioblastomas may be asymp-
tomatic or present with a visual field defect or a loss of visual activity due to retinal 
detachment, exudation, or hemorrhage. Retinal function tests are helpful in early detec-
tion of asymptomatic patients with quiescent retinal angiomas. The number of retinal 
angiomas does not appear to increase with age; however, there is greater likelihood of 
vision loss with age.
4. Renal manifestations of VHL include renal cysts or carcinomas. Renal cell carcinoma (RCC) 
is specifically of the clear cell subtype, which may develop either within a cyst or in the 
surrounding parenchyma. It occurs in 70% of affected individuals by sixth decade. RCC 
occurring in VHL is known to have similar growth kinetics as those of sporadic one [83]. 
A hallmark feature of clear cell renal cell carcinoma is that cells undergo a metabolic shift 
consistent with the Warburg effect. It is a leading cause of mortality in VHL syndrome, 
therefore, renal screening is very important [84].
5. Pancreatic cysts: Most pancreatic lesions in VHL are simple cysts that can be numerous in 
individuals with VHL. They rarely cause endocrine or exocrine insufficiency. Cysts in the 
head of the pancreas cause biliary obstruction.
6. Neuroendocrine tumors: 5–17% of individuals with VHL develop neuroendocrine tumors 
of the pancreas. They are not usually hormonally active and are slow growing. Malignant 
behavior has been observed in tumors >3 cm [85].
7. Pheochromocytoma: These may present with sustained or episodic hypertension or 
be totally asymptomatic, detected incidentally by an abdominal imaging procedure. 
Pheochromocytomas are usually located in one or both adrenal glands. They are usually 
benign, but malignant behavior has been reported.
8. Endolymphatic sac tumors: These are seen in approximately 10–16% of individuals with 
VHL syndrome, and in some instances, the associated uni- or bilateral hearing loss is the 
initial feature of the syndrome [86]. The onset of hearing loss is typically sudden; sever-
ity varies, but it is often severe to profound [87]. Vertigo or tinnitus is the presenting 
complaint.
Epididymal and broad ligament cystadenomas: Epididymal or papillary cystadenomas are 
relatively common in males with VHL syndrome. They rarely cause problems, unless bilat-
eral, in which case they may result in infertility. The equivalent, much less common, lesion in 
women is a papillary cystadenoma of the broad ligament.
5.3. Genetics
VHL is caused by mutations of the VHL tumor suppressor gene on the short arm of chromosome 
3 (3p25–26), and there are over 1500 known mutations to date. The VHL protein regulates the 
function of hypoxia inducible factor alpha (HIFα) by ubiquitinating it, leading to its degradation 
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[88]. In VHL, HIFα is not degraded and instead dimerizes with HIFβ to activate the transcription 
of a number of genes including vascular endothelial growth factor, platelet-derived growth factor 
B, and erythropoietin [89] leading to multiple tumor types in various organ systems (Figure 4).
5.4. Treatment
CNS Hemangioblastomas: Surgery is the treatment of choice. The correct use of microsurgical 
techniques and thorough understanding of the anatomy yields satisfactory results with mini-
mal morbidity and maximum functional recovery. Outcome depends upon the neurological 
status before surgery, site, and size of lesion [90]. Favorable results can be achieved by careful 
dissection of the tumor and preoperative embolization to prevent hemorrhage. The use of 
intraoperative ICG video angiography in recent years is very helpful for easily locating the 
minor feeding arteries and maintaining normal perfusion especially in spinal hemangioblas-
toma surgery [91]. Radiation may be considered if surgery is not suitable. Current medical 
therapy includes Bevacizumab, Vorinostat, and Dovitinib [92]. Extended periods of follow-up 
(5 years or more) are necessary to accurately assess the efficacy of nonsurgical therapies, such 
as chemotherapy and radiation therapy, and tumor stability. Current guidelines recommend 
that asymptomatic patients who present with a primary spinal cord tumor undergo observa-
tion. Symptomatic patients should undergo surgical resection as it promises acceptable rates 
of neurological improvements
Retinal hemangioblastomas: Most ophthalmologists favor prospective treatment of retinal 
(but not optic nerve) angiomas to avoid blindness. Laser photocoagulation is the treatment 
Figure 4. VHL binds to HIFα targeting it for proteosome degradation. With abnormal VHL protein, HIFα dimerizes 
with HIFβ and activates transcription of a number of genes involved in cell growth and differentiation (adapted with 
permission from Ref. [99]).
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of choice for retinal capillary hemangiomas in the peripheral areas with a diameter of less 
than one-fourth of a disc. Cryotherapy is suitable for larger peripheral lesions. Vitrectomies 
may be useful for cases in which tractional retinal detachment has occurred. Despite being 
the  mainstays of treatment, these procedures have their limitations; therefore, PDT (photo-
dynamic therapy) and intravitreal anti-vascular endothelial growth factor (VEGF) are being 
considered as treatment options. PDT can be helpful in reducing macular edema associated 
with RCH (retinal capillary hemangioma); however, it has limitations especially for jux-
tapapillary tumors [93]. VEGF has been tried recently, but the outcomes are variable [94].
Renal Tumors: Patients with clear cell renal cell carcinoma have limited therapeutic options, 
as it is unresponsive to chemotherapy and is highly resistant to radiation. Surgery is the 
best option for renal cell carcinoma. Depending on the size and location of the tumor, 
nephron-sparing or partial nephrectomy may be possible without compromising survival. 
Renal transplantation has been successful in individuals in whom bilateral nephrectomy 
was necessary. Interleukin-2 (IL-2) therapy has proved to be effective in patients with meta-
static RCC [95].
Pheochromocytomas: Surgical removal of the tumor has favorable outcome with few recur-
rences. Partial adrenalectomy is the treatment of choice in children and early screening is 
recommended [96].
Pancreatic cysts and neuroendocrine tumors: Pancreatic cysts do not require surgical removal; 
however, tumor needs surgical resection if there is a high risk of metastasis [97].
For VHL associated hemangioblastomas, yearly investigation for craniospinal hemangio-
blastoma by MRI and yearly screening and follow-up for retinal angiomas is recommended. 
Annual abdominal ultrasound with triennial CT imaging for abdominal masses is postu-
lated. Annual audiometry is to be performed for possible endolymphatic sac tumor; detailed 
radiographic imaging of the skull base should be performed upon abnormality in audi-
tory testing. Investigations for cystadenomas of the epididymis and broad ligament only 
are mandatory on indication. Annual investigation for pheochromocytoma is recommended 
[98].
5.5. Future directions
Extensive studies, assessing the efficacy of various drugs are in different phases of clinical 
trials. It includes the role of 17AAG (17-allylamino 17-demethoxygeldanamycin) on RCC 
and the effects of Sunitinib in VHL patients who are unresponsive to conventional treatment. 
EYE001 is an experimental drug that seems to have promising results for the treatment of 
retinal HBG and associated vision loss by decreasing VEGF production.
6. Conclusion
The phakomatoses constitute a complex group of neurocutaneous syndromes with cutane-
ous, ocular, and neural involvement. Mutations have been identified in a variety of genes 
affecting multiple aspects of cell cycle regulation including kinase signaling cascades such as 
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mTOR and Ras as well as transcription factors. Due to the multitude of disease manifestations 
in multiple organ systems, treatment options are limited. A more complete understanding of 
the molecular mechanisms underlying these important disorders will lead to the identifica-
tion of molecular targets for the development of new pharmacologic and biologic therapies.
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